We have a pipeline of novel small molecule compounds to address high unmet needs for cancer patients. Revere strives to help patients with advanced disease in cancers such as colorectal cancer and non-small cell lung cancer, especially those who are not eligible for available targeted therapies and immune-oncology drugs. Our first-in-class pipeline of drugs is aimed to help patients with few treatment options after they become resistant to standards of care.
